PASADENA, Calif.--(BUSINESS WIRE)--Calando Pharmaceuticals, a leading siRNA therapeutics company, announced today that the company has submitted an investigational new drug application (IND) to the U.S. Food and Drug Administration (FDA) to initiate a Phase I clinical trial using their lead anti-cancer compound, CALAA-01. The drug candidate is a targeted nanoparticle, comprised of a proprietary, non-chemically-modified siRNA against the M2 subunit of ribonucleotide reductase—a clinically-validated cancer target—formulated with Calando’s proprietary RONDEL™ (RNAi/Oligonucleotide Nanoparticle Delivery) polymer delivery system.
